STEMI, Wearables, and the Myth of Being Watched

From living rooms to cath labs: how symptom stories, smartwatch silences and system design quietly shape infarct size and survival.

Episode 153 of Parallax brings Dr Rakesh Shah into conversation with Dr Ankur Kalra to examine a problem that has resisted three decades of system optimisation in STEMI care: what happens before the patient reaches you.

We have refined door‑to‑balloon times. We have built regional STEMI networks. We have squeezed out in‑hospital delay until further gains flirt with the limits of physiology.

Yet the first sixty minutes of a myocardial infarction remain largely untouched.

Ischaemic time is not linear. The greatest myocardial salvage is front‑loaded into the earliest hours, and every extra 30 minutes of delay pushes one‑year mortality higher. But while reperfusion metrics inside hospitals have tightened, pre‑hospital delay in many cohorts still clusters in the 2–6‑hour range.pmc.ncbi.nlm.nih+2

As Dr Shah frames it,

“We have perfected what happens after the patient arrives. We have not redesigned what happens before.”

This episode is less about a device and more about a structural gap. A gap between symptom onset and system activation. A gap that continues to determine infarct size, remodelling, and long‑term heart failure risk long before the guidewire crosses the lesion.

The sixty‑minute problem

The biology has not changed: a substantial proportion of irreversible myocardial injury accrues in the first hour of coronary occlusion. What has also not meaningfully changed is the human behaviour that fills that hour.

Older adults with AMI still frequently present more than six hours after symptom onset, even in health systems that celebrate guideline‑level door‑to‑balloon performance. Registry data remind us that total ischemic time—not just cath‑lab metrics—tracks with mortality, particularly in patients with cardiogenic shock or out‑of‑hospital arrest.

The delay is rarely technical. It is cognitive.

Patients hesitate. They normalise and reinterpret symptoms. They avoid the emergency department because of cost, inconvenience, caring responsibilities, or the lingering memory of “false alarm” prior visits. During COVID‑era qualitative work, patients described complex, sometimes tortuous decision‑making before finally calling an ambulance, often swayed by a spouse or family member rather than their own risk appraisal.

As Dr Shah observes,

“The bottleneck is not the cath lab. It is the decision to seek care.”

Cardiology has engineered excellence inside hospitals. It has not yet fully engineered how risk, language and diagnostics reach patients’ kitchens, cars and workplaces. Where we have stepped outside—through public education, even simple SMS campaigns—onset‑to‑door times can fall and early presentation rates can rise several‑fold.

The illusion of ubiquitous ECG

There is a comforting narrative that electrocardiography is now “everywhere”. Consumer devices capture single‑lead tracings. Smartwatches flag atrial fibrillation and drive a step‑change in AF detection in high‑risk groups.

But rhythm monitoring is not infarct detection.

ST‑elevation myocardial infarction is a spatial diagnosis. It depends on precordial and limb‑lead relationships, not just the presence of organised QRS complexes. A single‑lead tracing, however elegant its interface, cannot substitute for a diagnostic twelve‑lead ECG in the patient with ongoing chest pain.

The distinction is not academic. When chest pain meets a watch that says “no AF detected” or “normal rhythm”, reassurance may be misplaced. The silence of a device calibrated to find atrial fibrillation can delay the call to emergency services and quietly lengthen total ischemic time.

As Dr Shah notes, cardiology has exported a feeling of continuous monitoring without exporting full diagnostic capability. The illusion of ubiquitous ECG risks widening, not narrowing, the pre‑hospital gap.

Towards a different first hour

The episode doesn’t stop at diagnosis of the problem; it sketches a concrete way to redesign that first hour.

Shah comes to it with an unusual trajectory: former practising interventionalist, now cardiologist, MBA from Oxford, and chief medical officer at Doctor’s Link, a virtual‑first cardiology company. His answer to the pre‑hospital gap is MHART – a virtual cardiology clinic built around a mobile, patient‑initiated 10–12‑lead ECG platform and a chronic‑disease wrapper that keeps it in the patient’s hand, not in a drawer.​

At its core, MHART tries to mobilise the one thing STEMI care still hasn’t: a diagnostic‑grade ECG that can be triggered by the patient at the moment of doubt, wherever they are. The system asks the questions you and I would ask in the ER, walks the patient through lead placement, captures a multi‑lead tracing rather than a rhythm strip, and transmits both narrative and ECG to the patient’s own cardiologist for adjudication. The aim is deliberately blunt: to compress symptom‑to‑treatment‑activation from the current four‑to‑six‑hour norm to something closer to 20–25 minutes.

Shah is explicit about the stakes. On their modelling, simply moving diagnosis upstream with MHART could prevent on the order of one hundred thousand cardiovascular deaths over a comparable time horizon, roughly an 11% absolute reduction in cardiovascular mortality attributable to earlier detection alone. In that context, a mobile, clinician‑anchored first‑hour strategy is framed not as a gadget, but as a requirement for sustainability.

What makes this more than a device story is the way the platform is designed to stay “front of mind.” A bi‑weekly check‑in, medication review and chronic‑care workflow mean patients are already used to opening the app and attaching the device long before the day they develop chest pain. When symptoms do appear, the behaviour is rehearsed rather than novel.

In Shah’s early prototype case during the first COVID wave, that familiarity translated into a six‑minute assessment at a kitchen table: symptom narrative, ECG, and a confident decision that avoided both unnecessary ER exposure and a missed event. Similar mobile 12‑lead and cloud‑based ECG systems have already shown that pre‑hospital tele‑ECG can shorten first‑medical‑contact‑to‑balloon time and reduce length of stay, particularly in systems that activate the cath lab from the field. MHART pushes that logic a step further by letting the patient initiate the process.

For cardiologists, the provocation is clear. The solution space for STEMI is no longer confined to stents, pumps and door‑to‑balloon algorithms. It now includes whether we are willing to co‑design and clinically own tools that move true twelve‑lead diagnostics into living rooms and restaurants, and whether we see that first, messy, human hour as part of our practice—or as someone else’s problem.

A different frontier for interventionalists

This conversation asks cardiologists—particularly interventionalists—to widen their field of view:

• What would it look like if our primary performance metric was not only door‑to‑balloon, but symptom‑to‑first‑medical‑contact, stratified by age, sex and socioeconomic status?

• How do we integrate wearables, virtual triage and community‑level ECG acquisition in a way that shortens time‑to‑diagnosis rather than inflating false reassurance?

• If simple SMS interventions can shift onset‑to‑door behaviour, what could a deliberately designed, cardiology‑led digital pre‑hospital pathway achieve at scale?

Rather than squeezing another few minutes from already‑lean cath‑lab workflows, Dr Shah and Dr Kalra argue that the next meaningful frontier in STEMI care sits upstream—in the first, messy, human sixty minutes, before the patient ever crosses your hospital’s threshold.